Harmony Biosciences Holdings (HRMY, Drugmakers) Stock Valuation & Fair Value
Mixed on our testsHarmony Biosciences Holdings (HRMY, Drugmakers) trades at a current P/E of 8.9, about 44% below its historical normal valuation, with a forward growth estimate of 12.6% and a PEG of 0.70. Priced at its historical normal P/E of 15.8 on the same blended earnings, the 2026-11-06 close of $33.11 corresponds to about $59.20 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $33.11 at the Nov 6 close, 10.7% below the 20-day average ($37.06) and 15.9% below the 50-day ($39.36).
- RSI (14) at 30.8.
- 52-week range $26.54 to $42.86: the price is 22.7% below the high and 24.8% above the low.
The Street vs SeerForecast
Wall Street's mean price target for HRMY is $48.08 across 12 analysts, 45.2% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Misses analyst estimates often (80%)
Verdict history
tickerseer's rating moved from strong on our tests (2026-07-31) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 29 readings
Frequently asked questions
Is Harmony Biosciences Holdings stock overvalued?
At a current P/E of 8.9 versus its historical normal P/E of 15.8, Harmony Biosciences Holdings trades about 44% below its typical valuation, with a PEG of 0.70 on 12.6% forward growth. tickerseer currently rates it mixed on our tests.
What is Harmony Biosciences Holdings's fair value and PEG?
Harmony Biosciences Holdings trades at a current P/E of 8.9 against a historical normal P/E of 15.8, a PEG of 0.70, and a forward growth estimate of 12.6%. Priced at its historical normal P/E of 15.8 on the same blended earnings, the 2026-11-06 close of $33.11 corresponds to about $59.20 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Harmony Biosciences Holdings changed?
tickerseer's rating moved from strong on our tests (2026-07-31) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Harmony Biosciences Holdings?
The mean Wall Street price target for Harmony Biosciences Holdings is $48.08 across 12 analysts, 45.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.